US9012147B2 - Method of enzymatic gene chip detection kit - Google Patents

Method of enzymatic gene chip detection kit Download PDF

Info

Publication number
US9012147B2
US9012147B2 US13/906,890 US201313906890A US9012147B2 US 9012147 B2 US9012147 B2 US 9012147B2 US 201313906890 A US201313906890 A US 201313906890A US 9012147 B2 US9012147 B2 US 9012147B2
Authority
US
United States
Prior art keywords
solution
temperature
reacted
gene chip
washing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US13/906,890
Other versions
US20140147841A1 (en
Inventor
Chan-Han Wu
Shiu-Ru Lin
Hsueh-Chiao Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CaryGene Biotechnology Corp
FOOYIN UNIVERSITY HOSPITAL
Original Assignee
CaryGene Biotechnology Corp
FOOYIN UNIVERSITY HOSPITAL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50773616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US9012147(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CaryGene Biotechnology Corp, FOOYIN UNIVERSITY HOSPITAL filed Critical CaryGene Biotechnology Corp
Assigned to CaryGene Biotechnology Corp., FOOYIN UNIVERSITY HOSPITAL reassignment CaryGene Biotechnology Corp. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIN, SHIU-RU, LIU, HSUEH-CHIAO, WU, CHAN-HAN
Publication of US20140147841A1 publication Critical patent/US20140147841A1/en
Application granted granted Critical
Publication of US9012147B2 publication Critical patent/US9012147B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/537—Protease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/125—Specific component of sample, medium or buffer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/507—Detection characterised by immobilisation to a surface characterised by the density of the capture oligonucleotide

Definitions

  • the present invention relates to detection with a gene chip; more particularly, relates to using a gene chip having 17 agents for clinical direct detection on blood without magnification.
  • RT-PCR reverse transcription polymerase chain reaction
  • real-time PCR PCR-time PCR
  • First problem pollution which caused false positive on detection.
  • Second one is related to RT-PCR, where, on comparing different samples, it is hard to control efficiency of sequence magnification.
  • Third one is interference on annearling between primers, where, on detecting gene groups, PCR-related technologies will take time, become complex and cost high.
  • Another prior art is a gene chip of weighted chemiluminescent membrane array (WCHMA). Abnormal situation of target K-ras over a target therapeutic drug for a lung cancer patient is analyzed.
  • WCHMA weighted chemiluminescent membrane array
  • the main purpose of the present invention is to use a gene chip for clinical direct detection on blood without magnification to provide high sensitivity and convenience at the same time.
  • the present invention is a method of an enzymatic gene chip detection kit, comprising steps of:
  • oligonucleotide segment for 384 ⁇ 576 min to obtain a hybridization solution, where an oligonucleotide segment is selected; the oligonucleotide segment comprises a plurality of target genes; two housekeeping genes are obtained to control reaction quality; the housekeeping genes fixes the oligonucleotide segment on the gene chip to obtain a specific sequence covered on the gene chip; and
  • FIG. 1 is the flow view showing the preferred embodiment according to the present invention.
  • FIG. 1 is a flow view showing a preferred embodiment according to the present invention.
  • the present invention is a method of an enzymatic gene chip detection kit.
  • the present invention uses an enzymatic gene chip detection kit, comprising a gene chip and a set of gene chip reagents.
  • the gene chip has two housekeeping genes for controlling quality of reactions of the gene chip.
  • the set of gene chip reagents comprises all reagents required in a flow of the reactions of the gene chip.
  • the flow of the reactions of the gene chip comprises RNA extraction, cDNA synthesis, probe labeling, hybridization and signal detection.
  • the gene chip requires 17 reagents for the reactions. After the reactions, expressions of the housekeeping genes are observed.
  • the present invention comprises the following steps:
  • RNA extraction 11 A sample is evenly mixed with 6 mAU of a protease K solution. Then, a lysis solution is added to be evenly mixed in.
  • the lysis solution comprises 200 millimoles (mM) of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 400 mM of sodium chloride (NaCl) and 1% of octyl phenoxy polyethoxy (Triton X-100).
  • a magnetic bead solution is added to be evenly mixed in, which is a solution of 25 mg/ml of hydroxyl-silicon dioxide magnetic bead.
  • the mixed solution is evenly mixed with a binding solution consisting 12.5% of polyethylene glycol (PEG) and 2 moles (M) of NaCl.
  • a binding solution consisting 12.5% of polyethylene glycol (PEG) and 2 moles (M) of NaCl.
  • PEG polyethylene glycol
  • M moles
  • a washing solution consisting 70% of ethanol, 1% of glycerin and 100mM of ammonium acetate, is evenly mixed in.
  • the magnetic beads are fixed by a magnet again for removing a reacting solution thus obtained.
  • RNA solution consisting 20 mM of tris-hydrogen chloride (Tris-HCl) and 1 mM of ethylenediaminetetraacetic acid (EDTA), is evenly mixed in. After the mixed solution is reacted at a temperature of 70° C. for 10 min, the magnetic beads are fixed by a magnet for collecting an RNA solution thus obtained.
  • Tris-HCl tris-hydrogen chloride
  • EDTA ethylenediaminetetraacetic acid
  • cDNA synthesis 12 After putting the RNA solution for reaction at a temperature of 70° C. for 10 min, a primer solution, consisting 300 nanograms per microliter (ng/ul) of oligo-dT primer and 100 ng/ul of random primer, is evenly mixed in. After putting the mixed solution for reaction at a temperature of 0° C. for 2 min, a reverse transcription solution, consisting 250 mM of Tris-HCl, 375 mM of potassium chloride (KCl), 15 mM of magnesium chloride (MgCl) and 100 mM of dithiothreitol (DTT), is evenly mixed in.
  • a reverse transcription solution consisting 250 mM of Tris-HCl, 375 mM of potassium chloride (KCl), 15 mM of magnesium chloride (MgCl) and 100 mM of dithiothreitol (DTT)
  • a reverse transcriptase solution consisting 200 units of reverse transcriptase MLV and 25 units of ribonuclease inhibitor (RNases inhibitor), is evenly mixed in. After putting the mixed solution for reaction at a temperature of 42° C. for 120 min, a cDNA solution is obtained.
  • RNases inhibitor ribonuclease inhibitor
  • Probe labeling 13 After putting the cDNA solution for reaction at a temperature of 95° C. for 5 min, the cDNA solution is reacted at a temperature of 0° C. for 2 min and, then, is added with a labeling solution evenly mixed in, where the labeling solution comprises 80 nanograms per milliliter (ng/ml) of random primer, 2 units per microliter (U/ul) of Klen Taq polymerase, 1 mM of deoxyadenosine triphosphate (dATP), 1 mM of deoxycytidine triphosphate (dCTP), 1 mM of deoxyguanosine triphosphate (dGTP), 0.6 mM of deoxythymidine triphosphate (dTTP), 0.4 mM of biotin-deoxyuridine triphosphate (biotin-dUTP), 20% of Klen Taq buffer and 20% of glycerin. After putting the mixed solution for reaction at a temperature of 42° C. for 240 min, a
  • Hybridization 14 A gene chip is put into a reaction chamber.
  • a hybridization solution consisting 10% of polyethylene glycol (PEG), 10% of sodium dodecyl sulfate (SDS) and 2 moles (M) of sodium chloride (NaCl), is evenly mixed in.
  • the probe solution is reacted at a temperature of 95° C. for 5 min and continuous reaction at a temperature of 0° C. for 2 min. After putting the mixed solution for reaction at a temperature of 42° C. for 10 min, the probe solution is added into the reaction chamber. After putting the mixed solution for reaction at a temperature of 42° C. for 480 min, a hybridization solution is obtained.
  • Signal detection 15 The hybridization solution is removed to leave the gene chip in the reaction chamber.
  • a first washing solution consisting 0.5% of SDS and 0.5 ⁇ of saline sodium citrate (SSC), is added and is removed after 5 min of reaction. In the same way, the first washing solution and is added and is removed again.
  • a second washing solution of 2 ⁇ of SSC is added and is removed after 5 min of reaction at a temperature of 42° C. In the same way, the second washing solution is added and is removed again.
  • a filling solution consisting 1.5% of blocking buffer, is added and removed after 30 min of reaction.
  • An antibody solution consisting 0.7 ug/ml of alkaline phosphatase-conjugated IgG anti-biotin, is added and removed after 90 min of reaction.
  • a third washing solution consisting 1% of SDS, 1% of octyl phenoxy polyethoxy and 1% of glycerin, is added and removed after 5 min of reaction. In the same way, the third washing solution is added and is removed again.
  • a chromogen solution consisting 1 ⁇ of 5-bromo-4-chloro-3-indolyl-phosphate/p-nitro-blue tetrazolium chloride (BCIP/NBT), is added for reaction at a temperature of 42° C. until signals are generated. Then, water is added for washing until signals stop generating. A detection result is finally obtained after drying.
  • the gene chip is a material coated with a nylon membrane or a thermoplastic composite;
  • the thermoplastic composite can be polypropylene (PP) or polymethyl methacrylate (PMMA).
  • PP polypropylene
  • PMMA polymethyl methacrylate
  • an oligonucleotide segment is selected; the oligonucleotide segment comprises a plurality of target genes; two housekeeping genes are used to control reaction quality; and, the housekeeping genes fixes the oligonucleotide segment on the gene chip to form a specific sequence covered on the gene chip.
  • the oligonucleotide segment is a synthetic oligonucleotide consisting in a solution; the solution has a density of 10 ⁇ 200 mM; the oligonucleotide segment has a length of 40 ⁇ 60 bases; specific sequence of each of the target genes are complement to the those of the other target genes; more than 30 normal liters (NL) of the solution of synthetic oligonucleotide is distributed on the gene chip to duplicate and arrange the oligonucleotide segment in a planned way; and, after being dried, the oligonucleotide segment is radiated by ultraviolet (UV) to be solidified.
  • UV ultraviolet
  • the present invention can be used in clinical tests, where direct test on blood is possible without magnification.
  • gene chip gene expressions in the blood are observed with high sensitivity and convenience.
  • the present invention is a method of an enzymatic gene chip detection kit, where direct test on blood is possible without magnification; and, with a gene chip fabricated according to the present invention, gene expressions in the blood are observed with high sensitivity and convenience.

Abstract

A gene chip is provided for detection. When used on clinical detection, the gene chip directly detects blood without magnification. Gene expressions are examined with high sensitivity and convenience simultaneously.

Description

TECHNICAL FIELD OF THE INVENTION
The present invention relates to detection with a gene chip; more particularly, relates to using a gene chip having 17 agents for clinical direct detection on blood without magnification.
DESCRIPTION OF THE RELATED ARTS
Analysis on gene overexpression improves clinical diagnosis. Related technologies includes northern blotting, reverse transcription polymerase chain reaction (RT-PCR) and real-time PCR. However, northern blotting requires a complex procedure and a lot of samples, which applied in study only and not for clinical use. RT-PCR and real-time PCR are simpler yet still have some problems. First problem is pollution which caused false positive on detection. Second one is related to RT-PCR, where, on comparing different samples, it is hard to control efficiency of sequence magnification. Third one is interference on annearling between primers, where, on detecting gene groups, PCR-related technologies will take time, become complex and cost high.
A prior art uses a nylon membrane array for cancer detection. An expression of multi-mRNA labeled object in peripheral blood is obtained. The expression level of the molecular label are evaluated through RT-PCR and the nylon membrane. Data are obtained from RT-PCR and the nylon membrane, which is limited by linear regression analysis. Results from these two origins show high co-relationship (r=0.979, P<0.0001). Another prior art is a gene chip of weighted chemiluminescent membrane array (WCHMA). Abnormal situation of target K-ras over a target therapeutic drug for a lung cancer patient is analyzed.
Although applications of nylon membrane gene chips for molecular diagnosis and drug evaluation are revealed, detection specificity is hard to improve since every gene is deemed equally important to a specific disease. Another prior art detects and analyzes mass samples rapidly, yet magnification is required beforehand. Direct detection on blood to observe gene expressions with a gene chip is still not available.
Hence, the prior arts do not fulfill all users' requests on actual use.
SUMMARY OF THE INVENTION
The main purpose of the present invention is to use a gene chip for clinical direct detection on blood without magnification to provide high sensitivity and convenience at the same time.
To achieve the above purpose, the present invention is a method of an enzymatic gene chip detection kit, comprising steps of:
(a) evenly mixing a sample, a protease solution and a lysis solution to be reacted at a temperature of 45˜67 Celsius degrees (° C.) for 8˜12 minutes (min); adding a magnetic bead solution and a binding solution to be evenly mixed in to be reacted at a temperature of 20˜30° C. for 8˜12 min; fixing magnetic beads in the magnetic bead solution with a magnet to remove a reacting solution thus obtained; adding a washing solution to be evenly mixed in; fixing magnetic beads with a magnet to remove a reacting solution thus obtained; adding an elution solution to be evenly mixed in to be reacted at a temperature of 56˜84° C. for 8˜12 min; fixing magnetic beads with a magnet to obtain an RNA solution;
(b) processing reaction to the RNA solution at a temperature of 56˜84° C. for 8˜12 min; adding a primer solution to be evenly mixed in to be reacted at a temperature of −0.5˜0.5° C. for 1.5˜2.5 min; adding a reverse transcription solution and a reverse transcriptase solution to be evenly mixed in to be reacted at a temperature of 34˜50° C. for 96˜144 min to obtain a cDNA solution;
(c) processing reaction to the cDNA solution at a temperature of 76˜114° C. for 4˜6 min; lowering a temperature to −0.5˜0.5° C. to process reaction for 1.5˜2.5 min; adding a labeling solution to be evenly mixed in to be reacted at a temperature of 34˜50° C. for 192˜288 min to obtain a probe solution;
(d) putting a gene chip in a reaction chamber; adding a hybridization solution to be evenly mixed in to be reacted at a temperature of 34˜50° C. for 8˜12 min; processing reaction to the probe solution at a temperature of 76˜114° C. for 4˜6 min; lowering a temperature of the probe solution to −0.5˜0.5° C. to be reacted for 1.5˜2.5 min; adding the probe solution into the reaction chamber to be reacted at a temperature of 34˜50° C. for 384˜576 min to obtain a hybridization solution, where an oligonucleotide segment is selected; the oligonucleotide segment comprises a plurality of target genes; two housekeeping genes are obtained to control reaction quality; the housekeeping genes fixes the oligonucleotide segment on the gene chip to obtain a specific sequence covered on the gene chip; and
(e) removing the hybridization solution to leave the gene chip in the reaction chamber; adding a first washing solution to be removed after 4˜6 min; adding the first washing solution to be removed after 4˜6 min again; adding a second washing solution at a temperature of 34˜50° C. to be removed after 4˜6 min; adding the second washing solution at the temperature of 34˜50° C. to be removed after 4˜6 min again; adding a blocking solution to be reacted for 24˜36 min and removed; adding an antibody solution to be reacted for 72˜108 min and removed; adding a third washing solution to be reacted for 4˜6 min and removed; adding a third washing solution to be reacted for 4˜6 min and removed again; adding a chromogen solution to be reacted at a temperature of 34˜50° C. to obtain signals; adding water to wash until signals stop; and drying the gene chip to obtain a final result.
Accordingly, a novel method of an enzymatic gene chip detection kit is obtained.
BRIEF DESCRIPTIONS OF THE DRAWINGS
The present invention will be better understood from the following detailed description of the preferred embodiment according to the present invention, taken in conjunction with the accompanying drawing, in which
FIG. 1 is the flow view showing the preferred embodiment according to the present invention.
 DESCRIPTION OF THE PREFERRED EMBODIMENT
The following description of the preferred embodiment is provided to understand the features and the structures of the present invention.
Please refer to FIG. 1, which is a flow view showing a preferred embodiment according to the present invention. As shown in the figure, the present invention is a method of an enzymatic gene chip detection kit. The present invention uses an enzymatic gene chip detection kit, comprising a gene chip and a set of gene chip reagents. The gene chip has two housekeeping genes for controlling quality of reactions of the gene chip. The set of gene chip reagents comprises all reagents required in a flow of the reactions of the gene chip. The flow of the reactions of the gene chip comprises RNA extraction, cDNA synthesis, probe labeling, hybridization and signal detection. The gene chip requires 17 reagents for the reactions. After the reactions, expressions of the housekeeping genes are observed. The present invention comprises the following steps:
(a) RNA extraction 11: A sample is evenly mixed with 6 mAU of a protease K solution. Then, a lysis solution is added to be evenly mixed in. The lysis solution comprises 200 millimoles (mM) of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 400 mM of sodium chloride (NaCl) and 1% of octyl phenoxy polyethoxy (Triton X-100). After the mixed solution is reacted at a temperature of 56 Celsius degrees (° C.) for 10 minutes (min), a magnetic bead solution is added to be evenly mixed in, which is a solution of 25 mg/ml of hydroxyl-silicon dioxide magnetic bead. Then, the mixed solution is evenly mixed with a binding solution consisting 12.5% of polyethylene glycol (PEG) and 2 moles (M) of NaCl. After the mixed solution is reacted at a temperature of 25° C. for 10 min, magnetic beads in the magnetic bead solution are fixed by a magnet for removing a reacting solution thus obtained. A washing solution, consisting 70% of ethanol, 1% of glycerin and 100mM of ammonium acetate, is evenly mixed in. The magnetic beads are fixed by a magnet again for removing a reacting solution thus obtained. An elution solution, consisting 20 mM of tris-hydrogen chloride (Tris-HCl) and 1 mM of ethylenediaminetetraacetic acid (EDTA), is evenly mixed in. After the mixed solution is reacted at a temperature of 70° C. for 10 min, the magnetic beads are fixed by a magnet for collecting an RNA solution thus obtained.
(b) cDNA synthesis 12: After putting the RNA solution for reaction at a temperature of 70° C. for 10 min, a primer solution, consisting 300 nanograms per microliter (ng/ul) of oligo-dT primer and 100 ng/ul of random primer, is evenly mixed in. After putting the mixed solution for reaction at a temperature of 0° C. for 2 min, a reverse transcription solution, consisting 250 mM of Tris-HCl, 375 mM of potassium chloride (KCl), 15 mM of magnesium chloride (MgCl) and 100 mM of dithiothreitol (DTT), is evenly mixed in. Then, a reverse transcriptase solution, consisting 200 units of reverse transcriptase MLV and 25 units of ribonuclease inhibitor (RNases inhibitor), is evenly mixed in. After putting the mixed solution for reaction at a temperature of 42° C. for 120 min, a cDNA solution is obtained.
(c) Probe labeling 13: After putting the cDNA solution for reaction at a temperature of 95° C. for 5 min, the cDNA solution is reacted at a temperature of 0° C. for 2 min and, then, is added with a labeling solution evenly mixed in, where the labeling solution comprises 80 nanograms per milliliter (ng/ml) of random primer, 2 units per microliter (U/ul) of Klen Taq polymerase, 1 mM of deoxyadenosine triphosphate (dATP), 1 mM of deoxycytidine triphosphate (dCTP), 1 mM of deoxyguanosine triphosphate (dGTP), 0.6 mM of deoxythymidine triphosphate (dTTP), 0.4 mM of biotin-deoxyuridine triphosphate (biotin-dUTP), 20% of Klen Taq buffer and 20% of glycerin. After putting the mixed solution for reaction at a temperature of 42° C. for 240 min, a probe solution is obtained.
(d) Hybridization 14: A gene chip is put into a reaction chamber. A hybridization solution, consisting 10% of polyethylene glycol (PEG), 10% of sodium dodecyl sulfate (SDS) and 2 moles (M) of sodium chloride (NaCl), is evenly mixed in. The probe solution is reacted at a temperature of 95° C. for 5 min and continuous reaction at a temperature of 0° C. for 2 min. After putting the mixed solution for reaction at a temperature of 42° C. for 10 min, the probe solution is added into the reaction chamber. After putting the mixed solution for reaction at a temperature of 42° C. for 480 min, a hybridization solution is obtained.
(e) Signal detection 15: The hybridization solution is removed to leave the gene chip in the reaction chamber. A first washing solution, consisting 0.5% of SDS and 0.5× of saline sodium citrate (SSC), is added and is removed after 5 min of reaction. In the same way, the first washing solution and is added and is removed again. A second washing solution of 2× of SSC is added and is removed after 5 min of reaction at a temperature of 42° C. In the same way, the second washing solution is added and is removed again. A filling solution, consisting 1.5% of blocking buffer, is added and removed after 30 min of reaction. An antibody solution, consisting 0.7 ug/ml of alkaline phosphatase-conjugated IgG anti-biotin, is added and removed after 90 min of reaction. A third washing solution, consisting 1% of SDS, 1% of octyl phenoxy polyethoxy and 1% of glycerin, is added and removed after 5 min of reaction. In the same way, the third washing solution is added and is removed again. A chromogen solution, consisting 1× of 5-bromo-4-chloro-3-indolyl-phosphate/p-nitro-blue tetrazolium chloride (BCIP/NBT), is added for reaction at a temperature of 42° C. until signals are generated. Then, water is added for washing until signals stop generating. A detection result is finally obtained after drying.
In step (d), the gene chip is a material coated with a nylon membrane or a thermoplastic composite; the thermoplastic composite can be polypropylene (PP) or polymethyl methacrylate (PMMA). Regarding the gene chip, an oligonucleotide segment is selected; the oligonucleotide segment comprises a plurality of target genes; two housekeeping genes are used to control reaction quality; and, the housekeeping genes fixes the oligonucleotide segment on the gene chip to form a specific sequence covered on the gene chip. Therein, the oligonucleotide segment is a synthetic oligonucleotide consisting in a solution; the solution has a density of 10˜200 mM; the oligonucleotide segment has a length of 40˜60 bases; specific sequence of each of the target genes are complement to the those of the other target genes; more than 30 normal liters (NL) of the solution of synthetic oligonucleotide is distributed on the gene chip to duplicate and arrange the oligonucleotide segment in a planned way; and, after being dried, the oligonucleotide segment is radiated by ultraviolet (UV) to be solidified. Thus, a gene chip is fabricated according to the present invention.
Hence, the present invention can be used in clinical tests, where direct test on blood is possible without magnification. With the gene chip, gene expressions in the blood are observed with high sensitivity and convenience.
To sum up, the present invention is a method of an enzymatic gene chip detection kit, where direct test on blood is possible without magnification; and, with a gene chip fabricated according to the present invention, gene expressions in the blood are observed with high sensitivity and convenience.
The preferred embodiment herein disclosed is not intended to unnecessarily limit the scope of the invention. Therefore, simple modifications or variations belonging to the equivalent of the scope of the claims and the instructions disclosed herein for a patent are all within the scope of the present invention.

Claims (20)

What is claimed is:
1. A method of an enzymatic gene chip detection kit, comprising steps of:
(a) evenly mixing a sample, a protease solution and a lysis solution to be reacted at a temperature of 45˜67 Celsius degrees (° C.) for 8-12 minutes (min); adding a magnetic bead solution and a binding solution to be evenly mixed in to be reacted at a temperature of 20˜30° C. for 8˜12 min; fixing magnetic beads in said magnetic bead solution with a magnet to remove a reacting solution thus obtained; adding a washing solution to be evenly mixed in; fixing magnetic beads with a magnet to remove a reacting solution thus obtained; adding an elution solution to be evenly mixed in to be reacted at a temperature of 56˜84° C. for 8˜12 min; fixing magnetic beads with a magnet to obtain an RNA solution;
(b) processing reaction to said RNA solution at a temperature of 56˜84° C. for 8˜12 min; adding a primer solution to be evenly mixed in to be reacted at a temperature of −0.5˜0.5° C. for 1.5˜2.5 min; adding a reverse transcription solution and a reverse transcriptase solution to be evenly mixed in to be reacted at a temperature of 34˜50° C. for 96˜144 min to obtain a cDNA solution;
(c) processing reaction to said cDNA solution at a temperature of 76˜114° C. for 4˜6 min; lowering a temperature to −0.5˜0.5° C. to process reaction for 1.5˜2.5 min; adding a labeling solution to be evenly mixed in to be reacted at a temperature of 34˜50° C. for 192˜288 min to obtain a probe solution;
(d) putting a gene chip in a reaction chamber; adding a hybridization solution to be evenly mixed in to be reacted at a temperature of 34˜50° C. for 8˜12 min; processing reaction to said probe solution at a temperature of 76˜114° C. for 4˜6 min; lowering a temperature of said probe solution to −0.5˜0.5° C. to be reacted for 1.5˜2.5 min; adding said probe solution into said reaction chamber to be reacted at a temperature of 34˜50° C. for 384˜576 min to obtain a hybridization solution,
wherein an oligonucleotide segment is selected; said oligonucleotide segment comprises a plurality of target genes; two housekeeping genes are obtained to control reaction quality; said housekeeping genes fixes said oligonucleotide segment on said gene chip to obtain a specific sequence covered on said gene chip; and
(e) removing said hybridization solution to leave said gene chip in said reaction chamber; adding a first washing solution to be removed after 4˜6 min; adding said first washing solution to be removed after 4˜6 min again; adding a second washing solution at a temperature of 34˜50° C. to be removed after 4˜6 min; adding said second washing solution at said temperature of 34˜50° C. to be removed after 4˜6 min again; adding a blocking solution to be reacted for 24˜36 min and removed; adding an antibody solution to be reacted for 72˜108 min and removed; adding a third washing solution to be reacted for 4˜6 min and removed; adding said third washing solution to be reacted for 4˜6 min and removed again; adding a chromogen solution to be reacted at a temperature of 34˜50° C. to obtain signals; adding water to wash until signals stop; and drying said gene chip to obtain a final result.
2. The method according to claim 1,
wherein said gene chip is selected from a group consisting of a nylon membrane and a thermoplastic composite and said thermoplastic composite is selected from a group consisting of polypropylene (PP) and polymethyl methacrylate (PMMA).
3. The method according to claim 1,
wherein said oligonucleotide segment is a synthetic oligonucleotide consisting in a solution and said solution has a density of 10˜200 millimoles (mM);
wherein said oligonucleotide segment has a length of 40˜60 bases and specific sequences of each of said target genes are complement to said specific sequences of the other target genes;
wherein more than 30 normal liters (NL) of said solution of synthetic oligonucleotide is distributed on said gene chip to duplicate and arrange said oligonucleotide segment and, after being dried, to be radiated by ultraviolet (UV) to be solidified.
4. The method according to claim 1,
wherein, in step (a), said protease solution is a solution of protease K.
5. The method according to claim 1,
wherein, in step (a), said lysis solution is a solution of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, sodium chloride (NaCl) and octyl phenoxy polyethoxy (Triton X-100).
6. The method according to claim 1,
wherein, in step (a), said magnetic bead solution is a solution of hydroxyl-silicon dioxide magnetic bead.
7. The method according to claim 1,
wherein, in step (a), said binding solution is a solution of polyethylene glycol (PEG) and NaCl.
8. The method according to claim 1,
wherein, in step (a), said washing solution is a solution of ethanol, glycerin and ammonium acetate.
9. The method according to claim 1,
wherein said elution solution is a solution of tris-hydrogen chloride (Tris-HCl) and ethylenediaminetetraacetic acid (EDTA).
10. The method according to claim 1,
wherein, in step (a), said primer solution is a solution of oligo-dT primer and random primer.
11. The method according to claim 1,
wherein, in step (b), said reverse transcription solution is a solution of Tris-HCl, potassium chloride (KCl), magnesium chloride (MgCl) and dithiothreitol (DTT).
12. The method according to claim 1,
wherein, in step (b), said reverse transcriptase solution is a solution of reverse transcriptase (MMLV) and ribonuclease inhibitor (RNases inhibitor).
13. The method according to claim 1,
wherein, in step (c), said labeling solution is a solution of random primer, Klen Taq polymerase, deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate (dGTP), deoxythymidine triphosphate (dTTP), biotin-deoxyuridine triphosphate (biotin-dUTP), Klen Taq buffer and glycerin.
14. The method according to claim 1,
wherein, in step (d), said hybridization solution is a solution of PEG, sodium dodecyl sulfate (SDS) and NaCl.
15. The method according to claim 1,
wherein, in step (e), said first washing solution is a solution of SDS and saline sodium citrate (SSC).
16. The method according to claim 1,
wherein, in step (e), said second washing solution is a solution of sodium citrate.
17. The method according to claim 1,
wherein, in step (e), said third washing solution is a solution of SDS, octyl phenoxy polyethoxy and glycerin.
18. The method according to claim 1,
wherein, in step (e), said filling solution is a solution of blocking buffer.
19. The method according to claim 1,
wherein, in step (e), said antibody solution is a solution of alkaline phosphatase-conjugated IgG anti-biotin.
20. The method according to claim 1,
wherein, in step (e), said chromogen solution is a solution of 5-Bromo-4-chloro-3-indolyl phosphate/p-nitro-blue tetrazolium chloride (BCIP/NBT).
US13/906,890 2012-11-28 2013-05-31 Method of enzymatic gene chip detection kit Expired - Fee Related US9012147B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TW101144416 2012-11-28
TW101144416A TWI509074B (en) 2012-11-28 2012-11-28 Enzyme Gene Chip Detection Reagent and Its Detection
TW101144416A 2012-11-28

Publications (2)

Publication Number Publication Date
US20140147841A1 US20140147841A1 (en) 2014-05-29
US9012147B2 true US9012147B2 (en) 2015-04-21

Family

ID=50773616

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/906,890 Expired - Fee Related US9012147B2 (en) 2012-11-28 2013-05-31 Method of enzymatic gene chip detection kit

Country Status (3)

Country Link
US (1) US9012147B2 (en)
CN (1) CN103849679B (en)
TW (1) TWI509074B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10252500B2 (en) * 2014-10-02 2019-04-09 Solutia Inc. Multiple layer interlayer resisting defect formation
US9809010B2 (en) * 2014-10-15 2017-11-07 Solutia Inc. Multilayer interlayer having sound damping properties over a broad temperature range
TWI703217B (en) * 2016-04-22 2020-09-01 康雋國際生物科技股份有限公司 High-performance mRNA labeling detection method
TWI732827B (en) * 2017-02-24 2021-07-11 大陸商蘇州翊準基因科技有限公司 Detection method of high-efficiency mRNA labeling detection reagent set
TWM567771U (en) * 2017-09-08 2018-10-01 翊准國際生物科技股份有限公司 High-performance mRNA marker auto-analysis device
CN108531548A (en) * 2018-04-09 2018-09-14 上海芯超生物科技有限公司 A kind of cell cDNA chip and its preparation method and application
CN110628762A (en) * 2019-10-14 2019-12-31 杭州同创越诚基因科技有限公司 Nucleic acid extraction method based on nano magnetic beads and application
CN112048401B (en) * 2020-08-28 2022-05-17 上海符贝基因科技有限公司 Micro-fluidic chip cleaning agent and method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011412A2 (en) * 2004-11-05 2007-01-25 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Diagnosis and prognosis of infectious diesease clinical phenotypes and other physiologic states using host gene expresion biomarkers in blood
CN101665785B (en) * 2009-09-24 2011-02-16 戴立忠 Method for extracting and purifying nucleic acid from samples by magnetic beads
TWI402502B (en) * 2010-05-13 2013-07-21 Fooyin University Hospital Genome detection system
CN102191339B (en) * 2011-03-30 2014-01-29 珠海出入境检验检疫局检验检疫技术中心 Preparation method and detection method for gene chip
CN102229925B (en) * 2011-05-13 2013-04-17 薛昱 Enhanced magnetic-bead-based nucleic acid extraction method

Also Published As

Publication number Publication date
CN103849679B (en) 2017-04-26
US20140147841A1 (en) 2014-05-29
CN103849679A (en) 2014-06-11
TW201420767A (en) 2014-06-01
TWI509074B (en) 2015-11-21

Similar Documents

Publication Publication Date Title
US9012147B2 (en) Method of enzymatic gene chip detection kit
JP7228514B2 (en) CRISPR effector system-based diagnostics
US11104937B2 (en) CRISPR effector system based diagnostics
Devonshire et al. Application of next generation qPCR and sequencing platforms to mRNA biomarker analysis
AU2018392709A1 (en) CRISPR effector system based multiplex diagnostics
CN108449933A (en) System and method for collecting the sample from Multiple-Aperture Device
JP2020513815A (en) Diagnostic method for virus detection based on clustered short repeat palindrome effector system
US20160228841A2 (en) Methods and compositions for tagging and analyzing samples
CN105934523A (en) Multiplex detection of nucleic acids
US10876106B2 (en) Gene analysis system
JP2022543051A (en) Single cell analysis
Lin et al. Degraded RNA transcript stable regions (StaRs) as targets for enhanced forensic RNA body fluid identification
Gao et al. MicroRNA (miRNA) profiling
US20200071692A1 (en) Method, systems and appratus for single cell analysis
WO2019079640A1 (en) Method, systems and apparatus for high-throughput single-cell dna sequencing with droplet microfluidics
US20220259653A1 (en) Dimer avoided multiplex polymerase chain reaction for amplification of multiple targets
US9617606B2 (en) Oligonucleotide for HIV detection, HIV detection kit, and HIV detection method
CN112143785A (en) Method for evaluating endometrial receptivity of a patient and kit for carrying out the method
JP2022082574A (en) Preparation of nucleic acid libraries from rna and dna
JP2009112195A (en) Method for detection/quantification of nucleic acid, and gene detection system
CN105506156B (en) Diagnose the molecular marker of osteosarcoma
CN105441565B (en) MiRNA as osteosarcoma diagnosis and treatment target
CN104404140B (en) A kind of preparation and application of microRNA colorimetric sensor
US20210340611A1 (en) Digital polymerase chain reaction method for detecting nucleic acids in samples
Bhattacharya et al. Experimental toolkit to study RNA level regulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: FOOYIN UNIVERSITY HOSPITAL, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, CHAN-HAN;LIN, SHIU-RU;LIU, HSUEH-CHIAO;REEL/FRAME:030525/0428

Effective date: 20130530

Owner name: CARYGENE BIOTECHNOLOGY CORP., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, CHAN-HAN;LIN, SHIU-RU;LIU, HSUEH-CHIAO;REEL/FRAME:030525/0428

Effective date: 20130530

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Expired due to failure to pay maintenance fee

Effective date: 20190421